Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
---|---|
Information provided by: | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
ClinicalTrials.gov Identifier: | NCT00408252 |
Preclinical studies as well as phase I and II trials have demonstrated that SU11248 has antitumor activity in renal cell carcinoma, breast cancer, neuroendocrine tumor and GIST. So at the light of these pre-clinical and clinical data, it seems interesting and promising to test SU011248 in these poor prognosis patients.
Condition | Intervention | Phase |
---|---|---|
Recurrent Disease Squamous Cell Head and Neck Carcinoma Palliative Treatment |
Other: biopsies Drug: SU011248 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study Of Su011248 In Patients With Recurrent And/Or Metastatic Squamous Head And Neck Carcinoma. |
Enrollment: | 38 |
Study Start Date: | February 2007 |
Estimated Study Completion Date: | December 2011 |
Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
This is an open-label phase II, multicenter study. Eligible patients will receive SU011248 in monotherapy (37.5 mg given continuously without interruption). Tumor check-up will be performed every 6-8 weeks. Treatment will be continued until disease progression or unacceptable toxicities according to the patient or the investigator (the median for treatment in renal cell study was 8 months).
Since, head and neck tumors are easily accessible for iterative biopsy, this study will offer the opportunity to get tumor biopsies before and after SU011248. Our study will allow translational research with biopsies at crucial timing: at baseline before any treatment, , during the treatment with SU011248 (cycle 1, between week 4 and 6), for patients with stable disease or partial response, a new biopsy will be performed at the time of disease progression to try to understand the mechanisms of tumor or resistance.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Belgium | |
Cliniques Universiatires St LUC UCL | |
Bruxelles, Belgium, 1200 | |
clinique Sainte Elisabeth | |
Namur, Belgium, 5000 | |
Clinique universiataire de Mont Godinnes UCL | |
Yvoir, Belgium, 5004 | |
France | |
Institut Gustave Roussy | |
Villejuif Cedex, France, 94805 | |
Centre G-f Leclerc | |
DIJON Cedex, France, 8021079 | |
Centre Alexis Vautrin | |
Nancy, France, 4511 | |
René Gauducheau | |
Saint Herblain Cedex, France, 44805 | |
Centre Jean Perrin | |
Clermont Ferrand, France, 263011 | |
CHU Bretonneau | |
Tours cedex 1, France, 37044 |
Principal Investigator: | Jean-Pascal H Machiels, MD PhD | Cliniques Universitaires St Luc |
Responsible Party: | Cliniques Universitaires Sain-Luc ( Professor Machiels ) |
Study ID Numbers: | GORTEC 2006-01, IIR Study A6181004 |
Study First Received: | December 4, 2006 |
Last Updated: | March 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00408252 History of Changes |
Health Authority: | Belgium: Ministry of Social Affairs, Public Health and the Environment |
recurrent or locally advanced cytokine failure |
Sunitinib Neoplasms, Squamous Cell Carcinoma, Squamous Cell Angiogenesis Inhibitors |
Recurrence Neoplasms, Glandular and Epithelial Carcinoma |
Disease Attributes Neoplasms by Histologic Type Antineoplastic Agents Growth Substances Physiological Effects of Drugs Angiogenesis Inhibitors Recurrence Pharmacologic Actions Carcinoma |
Neoplasms Pathologic Processes Sunitinib Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Neoplasms, Squamous Cell Carcinoma, Squamous Cell Neoplasms, Glandular and Epithelial |